These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 2568762)
21. Psychiatric pharmacotherapy and the schizophrenic defect. Molcan J; Floreánová L; Novotný V; Polák L; Rakús A; Motýlová A Act Nerv Super (Praha); 1973 May; 15(2):91. PubMed ID: 4148088 [No Abstract] [Full Text] [Related]
22. Alprazolam in the emergency treatment of schizophrenia. Monfort JC Am J Psychiatry; 1993 Feb; 150(2):358. PubMed ID: 8422106 [No Abstract] [Full Text] [Related]
23. Benzodiazepines in schizophrenia: prefrontal cortex atrophy predicts clinical response to alprazolam augmentation. Seeley WW; Turetsky N; Reus VI; Wolkowitz OM World J Biol Psychiatry; 2002 Oct; 3(4):221-4. PubMed ID: 12516314 [TBL] [Abstract][Full Text] [Related]
24. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Leong OK; Wong KE; Tay WK; Gill RC Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796 [TBL] [Abstract][Full Text] [Related]
25. Compliance in the long-term treatment of schizophrenia. Kane JM; Borenstein M Psychopharmacol Bull; 1985; 21(1):23-7. PubMed ID: 2858907 [No Abstract] [Full Text] [Related]
26. [Comparative study of delayed-action neuroleptics in psychiatric therapeutics]. Pellet J; Guyotat J; Marie-Cardine M; Dubor P; Favre-Tissot M; Caron F; Cottraux J J Med Lyon; 1972 Apr; 53(227):591-8. PubMed ID: 4404295 [No Abstract] [Full Text] [Related]
29. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. Dencker SJ J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744 [TBL] [Abstract][Full Text] [Related]
30. [Considerations on the use of long-acting neuroleptics in a mental health center]. Carotti P; Merli R Minerva Med; 1986 Sep; 77(34-35):1577-83. PubMed ID: 2876402 [TBL] [Abstract][Full Text] [Related]
32. Antipsychotic medication for early-episode schizophrenia. Bola JR; Kao DT; Soydan H Schizophr Bull; 2012 Jan; 38(1):23-5. PubMed ID: 22115777 [No Abstract] [Full Text] [Related]
33. [Is there a special indication for fluphenazine in therapy refractory hallucinations?]. Bechter K Nervenarzt; 1994 Nov; 65(11):798-801. PubMed ID: 7816159 [TBL] [Abstract][Full Text] [Related]
34. Neuroleptic-induced reductions in serum dopamine-beta-hydroxylase in schizophrenia. Goodnick PJ; Tong C; Duncavage MB; Meltzer HY Biol Psychiatry; 1983 Dec; 18(12):1485-8. PubMed ID: 6140962 [No Abstract] [Full Text] [Related]
35. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients. Jain RC; Ananth JV; Lehmann HE; Ban TA Curr Ther Res Clin Exp; 1975 Oct; 18(4):585-9. PubMed ID: 241609 [No Abstract] [Full Text] [Related]
37. Importance of oral glucose tolerance test in patient with schizophrenia. Margetić B; Aukst-Margetić B; Badanjak A Psychiatr Danub; 2005 Jun; 17(1-2):94-6. PubMed ID: 16395850 [TBL] [Abstract][Full Text] [Related]
38. Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions. Devito RA; Brink L; Sloan C; Jolliff F J Clin Psychiatry; 1978 Jan; 39(1):26-34. PubMed ID: 24614 [TBL] [Abstract][Full Text] [Related]
39. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Olfson M; Marcus SC; Ascher-Svanum H Schizophr Bull; 2007 Nov; 33(6):1379-87. PubMed ID: 17470444 [TBL] [Abstract][Full Text] [Related]
40. Treating depression in schizophrenia. Lund BC; Perry PJ; Miller DD Am J Psychiatry; 2001 Sep; 158(9):1528-9. PubMed ID: 11532750 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]